Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

CV Trials For Symptomatic Conditions Feasible But Not Always Practical, FDA Panel Says

Jun 23 2014

• By Sue Sutter

Related Content

NSAID Safety Review: FDA Panel Seeks Continued PRECISION From Pfizer

Feb 12 2014

Orexigen’s Big Plans On Hold As FDA Hashes Out Post-Marketing Requirements

Jun 11 2014

BioSante’s LibiGel Safety Study Concludes As Additional Efficacy Trials Loom On Horizon

Sep 04 2012

Takeda Positions Uloric To Gout Patients In Need Of Better Control

Feb 23 2009

Will CV Verdicts For <em>Onglyza</em>, <em>Nesina</em> Cause FDA To Change Its Tune On Antidiabetic Safety?

Sep 09 2013

Orexigen Hopes FDA Sees The LIGHT On Contrave NDA

Nov 25 2013

Related Companies

Cubist Pharmaceuticals, Inc.

AstraZeneca PLC

Salix Pharmaceuticals Ltd.

Takeda Pharmaceutical Co. Ltd.

Bristol Myers Squibb Company

ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals, Inc.

Pfizer Inc.

Orexigen Therapeutics, Inc.

Additional Topics

United States Advisory Committees Clinical Trials BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window